Skip to content 
Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Eocene Ltd. was formerly known as Galmed Pharmaceuticals Ltd. and changed its name to Eocene Ltd. in September 2026. Eocene Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel. more
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |||
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Cost of Revenue | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Gross Profit | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Gross Margin | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Operating Expenses | 17.65M | 7.49M | 6.28M | 8.51M | [{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":42.45,"profit":true},{"date":"2024-12-31","value":35.57,"profit":true},{"date":"2025-12-31","value":48.21,"profit":true}] | |
| Operating Income | (17.65M) | (7.49M) | (6.28M) | (8.51M) | [{"date":"2022-12-31","value":-1765100000,"profit":false},{"date":"2023-12-31","value":-749200000,"profit":false},{"date":"2024-12-31","value":-627800000,"profit":false},{"date":"2025-12-31","value":-851000000,"profit":false}] | |
| Total Non-Operating Income/Expense | (215.00K) | 580.00K | (1.24M) | (1.80M) | [{"date":"2022-12-31","value":-37.07,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-213.62,"profit":false},{"date":"2025-12-31","value":-310.17,"profit":false}] | |
| Pre-Tax Income | (17.87M) | (6.91M) | (7.52M) | (10.31M) | [{"date":"2022-12-31","value":-1786600000,"profit":false},{"date":"2023-12-31","value":-691200000,"profit":false},{"date":"2024-12-31","value":-751700000,"profit":false},{"date":"2025-12-31","value":-1030900000,"profit":false}] | |
| Income Taxes | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Income After Taxes | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Income From Continuous Operations | (17.87M) | (6.91M) | (7.52M) | (10.31M) | [{"date":"2022-12-31","value":-1786600000,"profit":false},{"date":"2023-12-31","value":-691200000,"profit":false},{"date":"2024-12-31","value":-751700000,"profit":false},{"date":"2025-12-31","value":-1030900000,"profit":false}] | |
| Income From Discontinued Operations | - | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] | |
| Net Income | (17.87M) | (6.91M) | (7.52M) | (10.31M) | [{"date":"2022-12-31","value":-1786600000,"profit":false},{"date":"2023-12-31","value":-691200000,"profit":false},{"date":"2024-12-31","value":-751700000,"profit":false},{"date":"2025-12-31","value":-1030900000,"profit":false}] | |
| EPS (Diluted) | (2.50K) | (256.57) | (73.36) | (20.02) | [{"date":"2022-12-31","value":-249697.18,"profit":false},{"date":"2023-12-31","value":-25657.16,"profit":false},{"date":"2024-12-31","value":-7335.96,"profit":false},{"date":"2025-12-31","value":-2001.81,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
| EOCN | |
|---|---|
| Current Ratio | 4.16 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| EOCN | |
|---|---|
| ROA (LTM) | -30.19% |
| ROE (LTM) | -68.21% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| EOCN | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.30 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.70 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| EOCN | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.30 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | 0.32 |
Eocene Ltd. (EOCN) share price today is $2.9
Yes, Indians can buy shares of Eocene Ltd. (EOCN) on Vested. To buy
Yes, you can purchase fractional shares of Eocene Ltd. (EOCN) via the Vested app. You can start investing in Eocene Ltd. (EOCN) with a minimum investment of $1.
You can invest in shares of Eocene Ltd. (EOCN) via Vested in three simple steps:
The 52-week high price of Eocene Ltd. (EOCN) is $12.32. The 52-week low price of Eocene Ltd. (EOCN) is $2.33.
The price-to-earnings (P/E) ratio of Eocene Ltd. (EOCN) is
The price-to-book (P/B) ratio of Eocene Ltd. (EOCN) is 0.30
The dividend yield of Eocene Ltd. (EOCN) is 0.00%
The market capitalization of Eocene Ltd. (EOCN) is $3.04M
The stock symbol (or ticker) of Eocene Ltd. is EOCN
Consider the share price of Eocene Ltd. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Eocene Ltd. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Eocene Ltd. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Eocene Ltd. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Eocene Ltd. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Eocene Ltd. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
